Mr. Brian Firth reports

GEMINA ANNOUNCES EXERCISE OF WARRANTS AND SHARES FOR DEBT ISSUANCE

Gemina Laboratories Ltd. has received aggregate gross proceeds of $435,000 from the exercise of 966,667 common share purchase warrants. Each warrant was exercisable at a price of 45 cents to purchase one common share of the company until July 16, 2024.

The company also announces that it has agreed to issue to certain lenders of the company an aggregate of 100,000 common shares of the company at an issue price of 40 cents per share in full and final settlement of financing related expenses owing by the company in the amount of $40,000 related to a 2023 loan. The common shares issued pursuant to the debt settlement will be subject to a statutory hold period of four months from the date of issuance under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.

About Gemina Laboratories Ltd.

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. The company's technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. The company's development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses.

We seek Safe Harbor.